Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
| Autor: | Budi O. Susanto, Elin M. Svensson, Lindsey te Brake, Rob E. Aarnoutse, Martin J. Boeree, Ulrika S.H. Simonsson |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Microbiology (medical)
Infectious Medicine Infektionsmedicin Pharmacology and Toxicology General Medicine Clinical trial simulation Farmakologi och toxikologi Farmaceutiska vetenskaper Pharmaceutical Sciences All institutes and research themes of the Radboud University Medical Center lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Infectious Diseases Tuberculosis Pharmacology (medical) Staggered dosing Rifampicin Model-based analysis |
| Zdroj: | International Journal of Antimicrobial Agents, 61, 6 International Journal of Antimicrobial Agents, 61 |
| ISSN: | 0924-8579 |
| Popis: | Contains fulltext : 293273.pdf (Publisher’s version ) (Open Access) BACKGROUND: Higher doses of rifampicin for tuberculosis have been shown to improve early bactericidal activity (EBA) and at the same time increase the intolerability due to high exposure at the beginning of treatment. To support dose optimisation of rifampicin, this study investigated new and innovative staggered dosing of rifampicin using clinical trial simulations to minimise tolerability problems and still achieve good efficacy. METHODS: Rifampicin population pharmacokinetics and time-to-positivity models were applied to data from patients receiving 14 days of daily 10-50 mg/kg rifampicin to characterise the exposure-response relationship. Furthermore, clinical trial simulations of rifampicin exposure were performed following four different staggered dosing scenarios. The simulated exposure after 35 mg/kg was used as a relative comparison for efficacy. Tolerability was derived from a previous model-based analysis relating exposure at day 7 and the probability of having adverse events. RESULTS: The linear relationship between rifampicin exposure and bacterial killing rate in sputum indicated that the maximum rifampicin EBA was not reached at doses up to 50 mg/kg. Clinical trial simulations of a staggered dosing strategy starting the treatment at a lower dose (20 mg/kg) for 7 days followed by a higher dose (40 mg/kg) predicted a lower initial exposure with lower probability of tolerability problems and better EBA compared with a regimen of 35 mg/kg daily. CONCLUSIONS: Staggered dosing of 20 mg/kg for 7 days followed by 40 mg/kg is predicted to reduce tolerability while maintaining exposure levels associated with better efficacy. 01 juni 2023 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect